The United States Food and Drugs Administration granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Aug. 3.

The U.S. Food and Drug Administration granted accelerated approval of Janssen’s Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.

Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.

FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumor to be surgically removed, and who have a […]

A study published in the journal Cell Stem Cell revealed how aging can cause lung regeneration to go awry, which can potentially lead to lung cancer and other diseases.

AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.

The U.S. Food and Drug Administration approved Tecentriq as a standalone therapy for an advanced form of lung cancer.

The American Lung Association announced a $25 million initiative to support the fight against COVID-19, as well as future viral pandemics.